JQ-1 Inhibits Colon Cancer Proliferation via Suppressing Wnt/β-Catenin Signaling and miR-21

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Bromodomain and extraterminal (BET) proteins are epigenetic regulators implicated in cancer.
• BET inhibitors represent a novel class of anti-cancer therapeutics.
• Colon cancer remains a significant health concern with ongoing needs for effective treatments.

Purpose of the Study:

• To investigate the therapeutic efficacy of JQ-1, a potent BET inhibitor, in colon cancer.
• To elucidate the underlying molecular mechanisms of JQ-1 action in colon cancer cells.
• To explore the role of Wnt signaling and miR-21 in JQ-1's anti-cancer effects.

Main Methods:

• Treatment of SW480 colon cancer mouse xenografts with JQ-1.
• Assessment of tumor growth, mouse survival, and apoptosis (Annexin V-FITC/PI flow cytometry).
• Analysis of H3K27 trimethylation (H3K27m3) at the p16 promoter (ChIP-qPCR), Wnt signaling components (Nkd2, β-catenin), and miR-21 levels (RT-PCR).
• MiR-21 overexpression studies using a lentiviral system to assess its interaction with JQ-1.

Main Results:

• JQ-1 significantly inhibited tumor growth, enhanced mouse survival, and induced apoptosis in colon cancer xenografts.
• JQ-1 epigenetically suppressed H3K27me3 promoter activity, leading to increased p16 expression.
• JQ-1 modulated Wnt signaling by upregulating Nkd2 and downregulating β-catenin.
• JQ-1 reduced miR-21 levels, and miR-21 overexpression partially rescued JQ-1's anti-proliferative effects and further downregulated Nkd2.

Conclusions:

• JQ-1 demonstrates significant efficacy as a colon cancer therapeutic.
• The mechanism of JQ-1 involves epigenetic modulation of p16, regulation of Wnt/β-catenin signaling, and suppression of miR-21.
• Targeting BET proteins offers a promising strategy for colon cancer treatment, potentially through combined modulation of epigenetic pathways and microRNAs.